Pharmafile Logo

ISPOR’s 2026–2027 HEOR Trends report: The Era of Evidence Judgment

January 27, 2026 | HEOR, Market Access, RWE, Top Trends, ispor, organization 

In response to ISPOR’s recently published 2026-2027 HEOR Trends, David Miller, CEO, Genesis Research Group, suggests that we’re no longer being evaluated on our ability to produce data, but on our ability to influence decisions under constraint.

- PMLiVE

Read ISPOR’s Top 10 HEOR Trends for 2026-2027 in isolation, and nothing seems radical. But as a system, the message is unmistakable. We have hit a structural inflection point in this industry.

For years, the mandate for HEOR organizations was simple: generate evidence.

Today, that mandate has shifted. We are no longer being evaluated on our ability to produce data; we are being judged on our ability to influence decisions under constraint. That requires adaptable teams, cross-functional perspectives, and the ability to evolve strategy in real-time.

The central question for leadership is no longer, “Can we generate the data?” That problem is largely solved. The question now is, “What evidence will have the most impact on decision-making?”

The selection problem

We are drowning in the data lakes. The explosion of AI and Real-World Evidence (RWE) means we can run almost any analysis we can dream up. But just because we can analyze everything doesn’t mean we should.

Abundance is becoming our biggest liability. Organizations that analyze everything will lose to those that curate. The advantage lies in distinguishing what is technically interesting from what is defensible under scrutiny. Many strategies quietly fail right here, mistaking volume for insight…

Read more

This content was provided by Genesis Research Group

Company Details

 Latest Content from  Genesis Research Group 

Genesis Research Group ISPOR Europe presentation ‘Planning with Insights: Even the Best Economic Models Need Validation’ features in scientific publication

We are pleased to share that The Evidence Base have carried out a 'deep dive' into a Genesis Research Group presentation on economic modeling in healthcare and harnessing stakeholder insights...

Genesis Research Group’s ISPOR Europe award-winning poster authors interviewed online

Genesis Research Group's poster 'Payer Perspective on the Impact of Real-world Evidence in Health Technology Assessments of Precision Oncology Treatments Across Europe: Results From an Online Survey' was recently named as...

Innovating Differently: A Conversation with David W. Miller, CEO of Genesis Research Group

A recent interview with Dr. David W. Miller, Chairman and CEO of Genesis Research Group, about his vision for the business, the changing face of research, and their unique value proposition...

Genesis Research Group unveils enhanced US market access data analytics

Genesis Research Group (“Genesis”), a pioneer of tech-enabled real-world evidence (RWE), health economics and outcomes research (HEOR), and market access services, announces the expansion of its real-world data analytics capabilities...

Assessing opportunities for manufacturers to communicate the value of therapies to oncology clinical pathway (OCP) developers

Based on insights from 15 U.S. payers and providers, this white paper explores how manufacturers can effectively engage oncology clinical pathway (OCP) developers.

Genesis Research Group Announces Participation of CEO David W. Miller in New ITN Business Healthcare Program

Genesis Research Group, led by newly appointed CEO, David W. Miller, is spotlighted in June’s launch of ITN Business’ “Advancing Healthcare” program for its ‘innovate differently’ approach to supporting life...

Alice Beer of ITN Business recently interviewed David W. Miller, CEO of Genesis Research Group, on ‘Advancing Healthcare’

ITN Business invited Genesis Research Group to contribute to a news style programme 'Advancing Healthcare' featuring key opinion leaders in the healthcare sector. Our CEO David W. Miller was one...

How does Genesis Research Group ‘Innovate differently’?

New Genesis Research Group CEO David W. Miller explains what we mean when we say we help our life science clients to 'Innovate differently' and transform the way they engage...

Envision Analogue – An Introduction

Powered by primary payer market research, Envision is an online platform that provides forward-looking evaluations and comprehensive strategic direction for market access viability after an oncology product has received positive...

World EPA Congress 2024: ‘Shining the light on vaccine market access’ by Genesis Research Group

A presentation with Katrin Nather, PhD, Associate Director, and Tijana Ignjatovic, Executive Director, Genesis Research Group. Contact solutions@genesisrg.com or visit www.genesisrg.com. With more and more innovative vaccines and immunization strategies...